Oncogenes and tumor angiogenesis: The question of vascular 'supply' and vascular 'demand'

Seminars in Cancer Biology

Volumn 14, Issue 2, 2004, Pages 93-104

  Rak, Janusz ^a   Yu, Joanne L ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Angiogenesis; Angiogenic phenotype; Anti angiogenic therapy; Apoptosis; Cancer; Colorectal cancer; Endothelial cells; Hypoxia; Oncogenes; p53; Ras; Tumor progression; Tumor suppressor genes; Vascular density

Indexed keywords

ANGIOGENESIS INHIBITOR; GEFITINIB; GROWTH FACTOR; IMATINIB; PROTEIN P53; RAS PROTEIN; RETINOIC ACID; TRASTUZUMAB;

ANGIOGENESIS; CANCER CELL; CANCER CONTROL; CANCER GROWTH; CANCER INVASION; CANCER THERAPY; CARCINOGENESIS; CELL SURVIVAL; CELL VIABILITY; GENE EXPRESSION PROFILING; GENE MUTATION; GENE TARGETING; HUMAN; HYPOXIA; ISCHEMIA; METASTASIS; ONCOGENE; PROTEOMICS; REVIEW; TUMOR VASCULARIZATION;

EID: 1242317802     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semcancer.2003.09.014     Document Type: Review

References (147)

1. Bishop J.M. Cancer: the rise of the genetic paradigm. Genes Dev. 9:1995;1309-1315.
2. Malumbres M., Barbacid M. Timeline: RAS oncogenes: the first 30 years. Nat. Rev. Cancer. 3:2003;459-465.
3. Fearon E.R., Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 61:1990;759-767.
4. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell. 100:2000;57-70.
5. Varmus H, Weinberg RA. Genes and the biology of cancer. New York: Scientific American Library; 1993.
6. McCormick F. Signal transduction networks. Ras as a paradigm. In: Rak J, editor. Oncogene-directed therapies. Totowa: Humana Press; 2003. p. 35-46.
7. Leevers S.J., Paterson H.F., Marshall C.J. Requirement for ras in raf activation is overcome by targeting raf to the plasma membrane. Nature. 369:1994;411.
8. Hunter T. Oncoprotein networks. Cell. 88:1997;333-346.
9. Murphy GA, Der CJ. Ras-mediated deregulation of gene expression and contribution to oncogenesis. In: Rak J, editor. Oncogene-directed therapies. Totowa: Humana Press; 2003. p. 77-100.
10. Bos J.L. The ras gene family and human carcinogenesis. Mutat. Res. 195:1988;255-271.
11. Arbiser J.L., Moses M.A., Ghiso N., Cao Y., Klauber N., Frank D.et al. Oncogenic H-ras stimulates angiogenesis by two distinct pathways. Proc. Natl. Acad. Sci. USA. 94:1997;861-866.
12. Holland E. The interplay between tumour suppressor genes and oncogenes in tumorigenesis. In: Rak J, editor. Oncogene-directed therapies. Totowa: Humana Press; 2003. p.101-12.
13. Lyden D., Young A.Z., Zagzag D., Yan W., Gerald W., O'Reilly R.et al. Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts. Nature. 401:1999;670-677.
14. Kinzler K.W., Vogelstein B. Landscaping the cancer terrain. Science. 280:1998;1036-1037.
15. Howe J.R., Roth S., Ringold J.C., Summers R.W., Jarvinen H.J., Sistonen P.et al. Mutations in the SMAD4/DPC4 gene in juvenile polyposis. Science. 280:1998;1086-1088.
16. Ylikorkala A., Rossi D.J., Korsisaari N., Luukko K., Alitalo K., Henkemeyer M.et al. Vascular abnormalities and deregulation of VEGF in Lkb1-deficient mice. Science. 293:2001;1323-1326.
17. Zhu Y., Ghosh P., Charnay P., Burns D.K., Parada L.F. Neurofibromas in NF1: Schwann cell origin and role of tumor environment. Science. 296:2002;920-922.
18. van der Weyden L., Jonkers J., Bradley A. Cancer: stuck at first base. Nature. 419:2002;127-128.
19. Done S, Squire JA. Genetic basis of cancer progression. In: Rak J, editor. Oncogene-directed therapies. Totowa: Humana Press; 2003. p. 3-18.
20. Folkman J. Tumor angiogenesis. Adv. Cancer Res. 43:1985;175-203.
21. Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285:1971;1182-1186.
22. Folkman J. Clinical applications of research on angiogenesis. N. Engl. J. Med. 333:1995;1757-1763.
23. Rak J., Filmus J., Kerbel R.S. Reciprocal paracrine interactions between tumor cells and endothelial cells. The "angiogenesis progression" hypothesis. Eur. J. Cancer. 32A:1996;2438-2450.
24. Skobe M., Rockwell P., Goldstein N., Vosseler S., Fusenig N.E. Halting angiogenesis suppresses carcinoma cell invasion. Nat. Med. 3:1997;1222-1227.
25. Brooks P.C., Stromblad S., Klemke R., Visscher D., Sarkar F.H., Cheresh D.A. Antiintegrin αbβ3 blocks human breast cancer growth and angiogenesis in human skin. J. Clin. Invest. 96:1995;1815-1822.
26. Fidler I.J. Angiogenic heterogeneity: regulation of neoplastic angiogenesis by the organ microenvironment. J. Natl. Cancer Inst. 93:2001;1040-1041.
27. Wojtukiewicz M.Z., Sierko E., Klement P., Rak J. The hemostatic system and angiogenesis in malignancy. Neoplasia. 3:2001;371-384.
28. Fernandez P.M., Rickles F.R. Tissue factor and angiogenesis in cancer. Curr. Opin. Hematol. 9:2002;401-406.
29. Nash G.F., Walsh D.C., Kakkar A.K. The role of the coagulation system in tumour angiogenesis. Lancet Oncol. 2:2001;608-613.
30. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1:1995;27-31.
31. Coussens L.M., Raymond W.W., Bergers G., Laig-Webster M., Behrendtsen O., Werb Z.et al. Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev. 13:1999;1382-1397.
32. Dvorak FH. Abnormalities of hemostasis in malignant disease. In: Coleman RB, Hirsh J, Marder VJ, Salzman JB, editors. Hemostasis and thrombosis: basic principles and clinical practice, 3rd ed. Philadelphia: Lippincott Company; 1994. p. 1238-54.
33. Relf M., LeJeune S., Scott P.A., Fox S., Smith K., Leek R.et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res. 57:1997;963-969.
34. Bouck N., Stellmach V., Hsu S.C. How tumors become angiogenic. Adv. Cancer Res. 69:1996;135-174.
35. Rastinejad F., Polverini P.J., Bouck N. Regulation of the activity of a new inhibitor by angiogenesis by a cancer suppressor gene. Cell. 56:1989;345-355.
36. Dameron K.M., Volpert O.V., Tainsky M.A., Bouck N. The p53 tumor suppressor gene inhibits angiogenesis by stimulating the production of thrombospondin. Cold Spring Harb. Symp. Quant. Biol. 59:1994;483-489.
37. Good D.J., Polverini P.J., Rastinejad F., Le Beau M.M., Lemons R.S., Frazier W.A.et al. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc. Natl. Acad. Sci. U.S.A. 87:1990;6624-6628.
38. Hanahan D., Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 86:1996;353-364.
39. O'Reilly M.S., Holmgren L., Shing Y., Chen C., Rosenthal R.A., Moses M. et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell. 79:1994;315-328.
40. Cao Y. Endogenous angiogenesis inhibitors and their therapeutic implications. Int. J. Biochem. Cell Biol. 33:2001;357-369.
41. Kalluri R. Basement membranes: structure assembly and role in tumor angiogenesis. Nat. Rev. Cancer. 3:2003;422-433.
42. O'Reilly M.S., Pirie-Shepherd S., Lane W.S., Folkman J. Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science. 285:1999;1926-1928.
43. Rak J., Klement G. Impact of oncogenes and tumor suppressor genes on deregulation of hemostasis and angiogenesis in cancer. Cancer Metastasis Rev. 19:2000;93-96.
44. Holmgren L., O'Reilly M.S., Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat. Med. 1:1995;149-153.
45. Rak J., Yu J.L., Klement G., Kerbel R.S. Oncogenes and angiogenesis: signaling three-dimensional tumor growth. J. Invest. Dermatol. Symp. Proc. 5:2000;24-33.
46. Rak J., Mitsuhashi Y., Bayko L., Filmus J., Sasazuki T., Kerbel R.S. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res. 55:1995;4575-4580.
47. Dvorak H.F., Brown L.F., Detmar M., Dvorak A.M. Review: vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am. J. Pathol. 146:1995;1029-1039.
48. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat. Rev. Cancer. 2:2002;795-803.
49. Shirasawa S., Furuse M., Yokoyama N., Sasazuki T. Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science. 260:1993;85-88.
50. Okada F., Rak J., St. Croix B., Lieubeau B., Kaya M., Roncari L.et al. Impact of oncogenes on tumor angiogenesis: mutant K-ras upregulation of VEGF/ VPF is necessary but not sufficient for tumorigenicity of human colorectal carcinoma cells. Proc. Natl. Acad. Sci. U.S.A. 95:1998;3609-3614.
51. Tokunaga T., Tsuchida T., Kijima H., Okamoto K., Oshika Y., Sawa N.et al. Ribozyme-mediated inactivation of mutant K-ras oncogene in a colon cancer cell line. Br. J. Cancer. 83:2000;833-839.
52. Grugel S., Finkenzeller G., Weindel K., Barleon B., Marme D. Both v-Ha-ras and v-raf stimulate expression of the vascular endothelial growth factor in NIH3T3 cells. J. Biol. Chem. 270:1995;25915-25919.
53. Rak J, Kerbel RS. Oncogenes and tumor angiogenesis. In: Rak J, editor. Oncogene-directed therapies. Totowa: Humana Press; 2003. p. 171-218.
54. Kerbel R.S., Folkman J. Clinical translation of angiogenesis inhibitors. Nat. Rev. Cancer. 2:2002;727-739.
55. Viloria-Petit A.M., Rak J., Hung M.-C., Rockwell P., Goldstein N., Kerbel R.S. Neutralizing antibodies against EGF and ErbB-2/neu receptor tyrosine kinases down-regulate VEGF production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am. J. Pathol. 151:1997;1523-1530.
56. Ciardiello F., Caputo R., Bianco R., Damiano V., Fontanini G., Cuccato S.et al. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin. Cancer Res. 7:2001;1459-1465.
57. Izumi Y., Xu L., diTomaso E., Fukumura D., Jain R.K. Herceptin acts as an anti-angiogenic cocktail. Nature. 416:2002;279-280.
58. Ebos J.M., Tran J., Master Z., Dumont D., Melo J.V., Buchdunger E.et al. Imatinib mesylate (STI-571) reduces Bcr-Abl-mediated vascular endothelial growth factor secretion in chronic myelogenous leukemia. Mol. Cancer Res. 1:2002;89-95.
59. Kini A.R., Peterson L.C., Tallman M.S., Lingen M.W. Angiogenesis in acute promyelocytic leukemia: induction by vascular endothelial growth factor and inhibition by all trans-retinoic acid. Blood. 97:2001;3919-3924.
60. Milanini J., Vinals F., Pouyssegur J., Pages G. p42/p44 MAP kinase module plays a key role in the transcriptional regulation of the vascular endothelial growth factor gene in fibroblasts. J. Biol. Chem. 273:1998;18165-18172.
61. Rak J., Mitsuhashi Y., Sheehan C., Tamir A., Viloria-Petit A., Filmus J.et al. Oncogenes and tumor angiogenesis: differential modes of vascular endothelial growth factor up-regulation in ras-transformed epithelial cells and fibroblasts. Cancer Res. 60:2000;490-498.
62. Oft M., Peli J., Rudaz C., Schwarz H., Beug H., Reichmann E. TGF-beta1 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells. Genes Dev. 10:1996;2462-2477.
63. Pal S., Datta K., Khosravi-Far R., Mukhopadhyay D. Role of protein kinase czeta in ras-mediated transcriptional activation of vascular permeability factor/vascular endothelial growth factor expression. J. Biol. Chem. 276:2001;2395-2403.
64. Sodhi A., Montaner S., Miyazaki H., Gutkind J.S. MAPK and Akt act cooperatively but independently on hypoxia inducible factor-1alpha in rasV12 upregulation of VEGF. Biochem. Biophys. Res. Commun. 287:2001;292-300.
65. Mazure N.M., Chen E.Y., Laderoute K.R., Giaccia A.J. Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt signaling pathway in Ha-ras-transformed cells through a hypoxia inducible factor-1 transcriptional element. Blood. 90:1997;3322-3331.
66. Mazure N.M., Chen E.Y., Yeh P., Laderoute K.R., Giaccia A.J. Oncogenic transformation and hypoxia synergistically act to modulate vascular endothelial growth factor expression. Cancer Res. 56:1996;3436-3440.
67. Berra E., Pages G., Pouyssegur J. MAP kinases and hypoxia in the control of VEGF expression. Cancer Metastasis Rev. 19:2000;139-145.
68. Feldkamp M.M., Lau N., Rak J., Kerbel R.S., Guha A. Normoxic and hypoxic regulation of vascular endothelial growth factor (VEGF) by astrocytoma cells is mediated by Ras. Int. J. Cancer. 81:1999;118-124.
69. Semenza G.L. Hypoxia, clonal selection, and the role of HIF-1 in tumor progression. Crit. Rev. Biochem. Mol. Biol. 35:2000;71-103.
70. Tsujii M., Kawano S., Tsuji S., Sawaoka H., Hori M., DuBois R.N. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell. 93:1998;705-716.
71. Irani K., Xia Y., Zweier J.L., Sollott S.J., Der C.J., Fearon E.R.et al. Mitogenic signaling mediated by oxidants in Ras-transformed fibroblasts. Science. 275:1997;1649-1652.
72. Sheng H., Williams C.S., Shao J., Liang P., DuBois R.N., Beauchamp R.D. Induction of cyclooxygenase-2 by activated Ha-ras oncogene in Rat-1 fibroblasts and the role of mitogen-activated protein kinase pathway. J. Biol. Chem. 273:1998;22120-22127.
73. Hurwitz H, Fehrenbacher L, Cartwright T, Hainsworth J, Heim W, Berlin J, et al. Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC. Abstracts ASCO 2003.
74. Ferrara N., Carver-Moore K., Chen H., Dowd M., Lu L., O'Shea K.S.et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature. 380:1996;439-442.
75. Shi Y.P., Ferrara N. Oncogenic ras fails to restore an in vivo tumorigenic phenotype in embryonic stem cells lacking vascular endothelial growth factor (VEGF). Biochem. Biophys. Res. Commun. 254:1999;480-483.
76. Grunstein J., Roberts W.G., Mathieu-Costello O., Hanahan D., Johnson R.S. Tumor-derived expression of vascular endothelial growth factor is a critical factor in tumor expansion and vascular function. Cancer Res. 59:1999;1592-1598.
77. Grunstein J., Masbad J.J., Hickey R., Giordano F., Johnson R.S. Isoforms of vascular endothelial growth factor act in a coordinate fashion to recruit and expand tumor vasculature. Mol. Cell Biol. 20:2000;7282-7291.
78. Tsuzuki Y., Fukumura D., Oosthuyse B., Koike C., Carmeliet P., Jain R.K. Vascular endothelial growth factor (VEGF) modulation by targeting hypoxia-inducible factor-1alpha → hypoxia response element → VEGF cascade differentially regulates vascular response and growth rate in tumors. Cancer Res. 60:2000;6248-6252.
79. Inoue M., Hager J.H., Ferrara N., Gerber H.P., Hanahan D. VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis. Cancer Cell. 1:2002;193-202.
80. Garber K. Angiogenesis inhibitors suffer new setback. Nat. Biotechnol. 20:2002;1067-1068.
81. Kuenen B.C., Rosen L., Smit E.F., Parson M.R., Levi M., Ruijter R.et al. Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. J. Clin. Oncol. 20:2002;1657-1667.
82. Yoshiji H., Harris S.R., Thorgeirsson U.P. Vascular endothelial growth factor is essential for initial but not continued in vivo growth of human breast carcinoma cells. Cancer Res. 57:1997;3924-3928.
83. Chin L., Tam A., Pomerantz J., Wong M., Holash J., Bardeesy N.et al. Essential role for oncogenic Ras in tumour maintenance. Nature. 400:1999;468-472.
84. Larcher F., Franco M., Bolontrade M., Rodriguez-Puebla M., Casanova L., Navarro M.et al. Modulation of the angiogenesis response through Ha-ras control, placenta growth factor, and angiopoietin expression in mouse skin carcinogenesis. Mol. Carcinog. 37:2003;83-90.
85. Viloria-Petit A., Miquerol L., Yu J.L., Gertsenstein M., Sheehan C., May L.T.et al. Contrasting effects of VEGF gene disruption in embryonic stem cell derived teratomas versus oncogene-induced tumors. EMBO J. 22:2003;4091-4102.
86. Zabrenetzky V., Harris C.C., Steeg P.S., Roberts D.D. Expression of the extracellular matrix molecule thrombospondin inversely correlates with malignant progression in melanoma, lung and breast carcinoma cell lines. Int. J. Cancer. 59:1994;191-195.
87. Watnick R.S., Cheng Y.-N., Rangarajan A., Ince T.A., Weinberg R.A. Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis. Cancer Cell. 3:2003;219-231.
88. Lawler J. Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth. J. Cell Mol. Med. 6:2002;1-12.
89. Streit M., Velasco P., Brown L.F., Skobe M., Richard L., Riccardi L.et al. Overexpression of thrombospondin-1 decreases angiogenesis and inhibits the growth of human cutaneous squamous cell carcinomas. Am. J. Pathol. 155:1999;441-452.
90. Kerbel R.S. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. BioEssays. 13:1991;31-36.
91. Rak J., Kerbel R.S. Treating cancer by inhibiting angiogenesis: new hopes and potential pitfalls. Cancer Metastasis Rev. 15:1996;231-236.
92. Kerbel R.S., Yu J., Tran J., Man S., Viloria-Petit A., Klement G.et al. Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches. Cancer Metastasis Rev. 20:2001;79-86.
93. Mukhopadhyay D., Tsiokas L., Zhou X.-M., Foster D., Brugge J.S., Sukhatme V.P. Hypoxic induction of human vascular endothelial growth factor expression through c-src activation. Nature. 375:1995;577-581.
94. Rak J.W., Yu J.L., Kerbel R.S., Coomber B.L. What do oncogenic mutations have to do with angiogenesis/vascular dependence of tumors? Cancer Res. 62:2002;1931-1934.
95. Yu J.L., Rak J.W., Carmeliet P., Nagy A., Kerbel R.S., Coomber B.L. Heterogeneous vascular dependence of tumor cell populations. Am. J. Pathol. 158:2001;1325-1334.
96. Yu J.L., Rak J.W., Coomber B.L., Hicklin D.J., Kerbel R.S. Effect of p53 status on tumor response to antiangiogenic therapy. Science. 295:2002;1526-1528.
97. Brown E.B., Campbell R.B., Tsuzuki Y., Xu L., Carmeliet P., Fukumura D. et al. In vivo measurement of gene expression, angiogenesis and physiological function in tumors using multiphoton laser scanning microscopy. Nat. Med. 7:2001;864-868.
98. Blagosklonny M.V. Hypoxia-inducible factor: Achilles' heel of antiangiogenic cancer therapy. Int. J. Oncol. 19:2001;257-262. [review].
99. Bunz F., Hwang P.M., Torrance C., Waldman T., Zhang Y., Dillehay L.et al. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J. Clin. Invest. 104:1999;263-269.
100. Graeber T.G., Osmanian C., Jacks T., Housman D.E., Koch C.J., Lowe S.W. et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature. 379:1996;88-91.
101. Harris A.L. Hypoxia - a key regulatory factor in tumour growth. Nat. Rev. Cancer. 2:2002;38-47.
102. Abdalla S.A., Behzad F., Bsharah S., Kumar S., Amini S.K., O'Dwyer S.T. et al. Prognostic relevance of microvessel density in colorectal tumours. Oncol. Rep. 6:1999;839-842.
103. Hlatky L., Hahnfeldt P., Folkman J. Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J. Natl. Cancer Inst. 94(19):2002;883-893.
104. Giaccia A. Genetic basis of altered responsiveness of cancer cells to their microenvironment. In: Rak J, editor. Oncogene-directed therapies. Totowa: Humana Press; 2003. p. 113-32.
105. Bedi A., Pasricha P.J., Akhtar A.J., Barber J.P., Bedi G.C., Giardiello F.M.et al. Inhibition of apoptosis during development of colorectal cancer. Cancer Res. 55:1995;1811-1816.
106. Gandara D.R., Lara P.N. Jr., Goldberg Z., Le Q.T., Mack P.C., Lau D.H.et al. Tirapazamine: prototype for a novel class of therapeutic agents targeting tumor hypoxia. Semin. Oncol. 29:2002;102-109.
107. Fletcher L. Approval heralds new generation of kinase inhibitors? Nat. Biotechnol. 19:2001;599-600.
108. Laughner E., Taghavi P., Chiles K., Mahon P.C., Semenza G.L. Her2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (hif-1alpha) synthesis: novel mechanism for hif-1-mediated vascular endothelial growth factor expression. Mol. Cell Biol. 21:2001;3995-4004.
109. Zhong H., Chiles K., Feldser D., Laughner E., Hanrahan C., Georgescu M.M.et al. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res. 60:2000;1541-1545.
110. Mayerhofer M., Valent P., Sperr W.R., Griffin J.D., Sillaber C. BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin. Blood. 100:2002;3767-3775.
111. Li M., Ye C., Feng C., Riedel F., Liu X., Zeng Q.et al. Enhanced antiangiogenic therapy of squamous cell carcinoma by combined endostatin and epidermal growth factor receptor-antisense therapy. Clin. Cancer Res. 8:2002;3570-3578.
112. Ciardiello F., Caputo R., Damiano V., Caputo R., Troiani T., Vitagliano D.et al. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin. Cancer Res. 9:2003;1546-1556.
113. Laird A.D., Vajkoczy P., Shawver L.K., Thurnher A., Liang C., Mohammadi M.et al. Cherrington SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res. 60:2000;4152-4160.
114. St. Croix B., Rago C., Velculescu V., Traverso G., Romans K.E., Montgomery E.et al. Genes expressed in human tumor endothelium. Science. 289:2000;1197-1202.
115. Arbiser J.L., Petros J., Klafter R., Govindajaran B., McLaughlin E.R., Brown L.F.et al. Reactive oxygen generated by Nox1 triggers the angiogenic switch. Proc. Natl. Acad. Sci. U.S.A. 99:2002;715-720.
116. Mukhopadhyay D., Tsiokas L., Sukhatme V.P. Wild-type p53 and v-src exert opposing influences on human vascular endothelial growth factor gene expression. Cancer Res. 55:1995;6161-6165.
117. Bein K., Ware J.A., Simons M. Myb-dependent regulation of thrombospondin 2 expression. Role of mRNA stability. J. Biol. Chem. 273:1998;21423-21429.
118. Jiang B.H., Agani F., Passaniti A., Semenza G.L. V-src induces expression of hypoxia4nducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression. Cancer Res. 57:1997;5328-5335.
119. Slack J.L., Bornstein P. Transformation by v-src causes transient induction followed by repression of mouse thrombospondin 1. Cell Growth Differ. 5:1994;1373-1380.
120. Meitar D., Crawford S.E., Rademaker A.W., Cohm S.L. Tumor angiogenesis correlates with metastatic disease, N-myc amplification and poor outcome in human neuroblastoma. J. Clin. Oncol. 14:1996;405-414.
121. Fotsis T., Breit S., Lutz W., Rossler J., Hatzi E., Schwab M.et al. Down-regulation ondothelial cell growth inhibitors by enhamnced MYCN oncogene expression in human neuroblastoma cells. Eur. J. Biochem. 263:1999;757-764.
122. Hatzi E., Breit S., Zoephel A., Ashman K., Tonysch U., Ahoru H.et al. MYGN oncogene and angiogenesis: down-regulation of endothelial growth inhibitors in human neuroblastoma cells. Purification, structural and functional characterization. Adv. Exp. Med. Biol. 476:2000;239-248.
123. Hatzi E, Murphy C, Zoephel A, Rasmussen H, Morbidelli L, Ahoru H. et al. N-myc oncogene overexpression down-regulates IL-6; evidence that IL-6 inhibits angiogenesis and suppresses neuroblastoma tumor growth. Oncogene; 21:3552-61.
124. Pelengaris S., Littlewood T., Khan M., Elia G., Evan G. Reversible activation of a complex neoplastic phenotype by a single oncogenic lesion. Mol. Cell. 3:1999;565-577.
125. Charoenrat P., Rhys-Evans P., Modjtahedi H., Eccles S.A. Vascular endothelial growth factor family members are differentially regulated by e-erb B signalling in head and neck squamous carcinoma cells. Clin. Exp. Metastasis. 18:2000;155-161.
126. Yen L, You XI, Al Moustafa AE, Batist G, Hymes NE, Mader S, et al. Heregulin selectively upregulates vascular endothelial Growth factor secretion in cancer cells and stimulates angiogenesis. Oncogene 31: 3460-9.
127. Baudino T.A., McKay C., Pendeville-Samain H., Nilsson J.A., Maclean K.H., White E.L.et al. C-Myc is essential for vasculogenesis and angiogenesis during development and tumor progression. Genes and Dev. 16:2002;2530-2543.
128. Ciardiello F., Damiano V., Bianco R., Bianco C., Fontanini G., De Laurentiis M.et al. Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A. J. Natl. Cancer Inst. 88:1996;1770-1776.
129. Perrotte P., Matsumoto T., Inoue K., Kuniyasu H., Eve B.Y., Hicklin D.J.et al. Anti-epidermal growth factor receptor antibody C225 inhibits Angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin. Cancer Res. 5:1999;257-265.
130. Fernandez A., Udagawa T., Schwesinger C., Beeckeu W., Achille-Gerte E., McDonnell T.et al. Angiogenic potential of prostate carcinoma cells overexpressing bcl-2. J. Natl. Cancer Inst. 93:2001;208-213.
131. Sheibani N., Frazier W.A. Repression of thrombospondin-1 expression, a natural inhibitor of angiogenesis in polyoma middle T transformed NIH 373 cells. Cancer Letts. 107:1996;45-52.
132. Saez E., Rutberg S.E., Mueller E., Oppenheim H., Smoluk J., Yuspa S.H.et al. c-fos is required for malignant progression for skin tumors. Cell. 82:1995;721-732.
133. McGregor L.M., McCune B.K., Graff J.R., McDowell P.R., Romans K.E., Yancopoulos G.D.et al. Roles of trk family Neurotrophin receptors in medullary thyroid carcinoma development and progression. Proc. Natl. Acad. Sci. USA. 96:1999;4540-4545.
134. Eggert A., Grotzer M.A., Ikegaki N., Liu X.G., Evans A.E., Brodeur G.M. Expression of neurotrophim receptor TrkA inhibits angiogenesis in neuroblastoma. Med. Pediatr. Oncol. 35:2000;568-572.
135. Le Buamec H., D'Anna R., Lachgar A., Zagury J.F., Bernard J., Ittele D. et al. HPV-16 E7 but not E6 oncogenic protein triggers both cellular immunosuppression and angiogenic processes. Biomed. Pharmacother. 53:1999;424-431.
136. Lopez-Deejo O., Viloria-Petit A., Beguet-Romero M., Mukhopadhyay D., Rak J., Kerbel R.S. Oncogenes and tumor angiogenesis: the HPV-16 E6 oncoprotein Activates the vascular growth factor (VEGF) gene promoter in a p53 Independent manner. Oncogene. 19:2000;4611-4620.
137. Bequet-Romero M., Lopez-Ocejo O. Angiogenesis modulators expression in culture cell lines positive for HPV-16 oncoproteins. Biochem. Biophys. Res. Commun. 277:2000;55-61.
138. Zietz C., Rossle M., Haas C., Sendelhofert A., Hirschmann A., Sturzl M. et al. MDM-2 oncoprotein overexpression, p53 gene mutation and VEGF upregulation in angiosarcomas. Am. J. Pathol. 153:1998;1425-1433.
139. Jiang B.H., Zheng J.Z., Aoki M., Vogt P.K. Phosphatidylinositol 3-kinase signalling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells. Proc. Natl. Acad. Sci. USA. 97:2000;1749-1753.
140. Auvinen M., Laine A., Paasinen-Sohns A., Kangas L., Saksela O., Andersson L.C.et al. Human ornithine decarboxylase-overproducing NIH 3T3 cells induce rapidly growing highly vascularized tumors in nude mice. Cancer Res. 57:1997;3016-3025.
141. Heaney A.P., Horwitz G.A., Wang Z., Singson R., Melmed S. Early involvement of estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolaetinoma pathogenesis. Nat. Med. 5:1999;1317-1321.
142. Fu X., Roberts W.G., Nobile V., Shapiro R., Kamps M.P. m Angiogenin-3, a target gene of oncoprotein E2a-P6x 1, encodes a new angiogenic member of the angiogenin family. Growth Factors. 17:1999;125-137.
143. White F.C., Benehacene A., Scheele J.S., Kamps M. VEGF mRNA is stabilized by ras and tyrosine kinase oncogenes, as well as by UV radiation-evidence for divergent stabilization pathways. Growth Factors. 14:1997;199-212.
144. van Golen K.L., Wu Z.F., Qiao X.T., Bao L., Merajver S.D. RhoC GTPase overexpression modulates induction of angiogenic factors in breast cells. Neoplasia. 2:2000;418-425.
145. Bais C., Santomasso B., Coso D., Arvanitakis L., Raaka E.G., Gutkind J.S.et al. G-protein-coupled receptor of Kaposi's sarcoma-associated herpes virus is a viral oncogene and angiogenesis activator. Nature. 391:1998;86-89.
146. Sodhi A., Montaner S., Patel V., Zohar M., Bais C., Mesri B.A.et al. The Kaposis's sarcoma-associated herpes virus G protein-coupled receptor up-Regulates vascular endothelial growth factor expression and secretion through mitogen-activated protein kinase and p38 pathways acting on hypoxia-inducible factor1 alpha. Cancer Res. 60:2000;4873-4880.
147. Kevil C.G., De Bendetti A., Payne D.K., Coe L.L., Laroux P.S., Alexander J.S. Translational regulation of vascular permeability factor by eukaryotic initiation factor 4E: implications for tumor angiogenesis. Int. J. Cancer. 65:1996;785-790.